Topline data were announced from a phase 3 trial evaluating setmelanotide for the treatment of acquired hypothalamic obesity.

Rhythm's Phase 3 trial shows setmelanotide significantly reduced BMI in rare hypothalamic obesity without new safety concerns over 52 weeks.

A group of children and adults with hypothalamic obesity receiving setmelanotide for 1 year had nearly a 20% greater BMI reduction than those receiving placebo, according to top-line results released ...

Despite the success of drugs like Ozempic (semaglutide) in promoting both weight loss and longer life, doubt remains about the role of body mass index (BMI) at older ages. Many studies have shown that ...